![Joanne Euden](https://profiles-cardiff.imgix.net/attachments/683?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Joanne Euden
(hi/ei)
Timau a rolau for Joanne Euden
Cymrawd Ymchwil – Uwch Reolwr Treial
Trosolwyg
Yn Gymrawd Ymchwil yn yr Is-adran Heintiau, Llid ac Imiwnedd yn y Ganolfan Ymchwil Treialon (CTR), fi yw'r arweinydd thema ar gyfer Clefydau Heintus yn yr is-adran. Cyn pontio i ymchwil clincial, roeddwn yn ymchwilydd ôl-ddoethurol yn Sefydliad Ymchwil y Galon Cymru (WHRI) ym Mhrifysgol Caerdydd.
Mae fy niddordebau mewn Profi Pwynt Gofal (POCT) a diagnosteg clefydau heintus gyda diddordeb arbennig mewn gofal eilaidd (Meddygaeth Brys). Fodd bynnag, bydd unrhyw dreial/astudiaeth sy'n gweithio tuag at wella gofal cleifion trwy weithredu ymyriadau newydd a gwell i'r GIG yn ennill fy niddordeb!
Mae treialon gweithredol rwy'n gweithio arnynt yn cynnwys:
COETHI
TRETH (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/excise)
PARCH (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/esteem)
EVITA (https://fundingawards.nihr.ac.uk/award/NIHR162027)
Astudiaethau Blaenorol:
PRONTO (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/pronto)
PEACH (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/peach)
AMDDIFFYNIAD CYFLYM (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/rapid-protection)
ENCEPH-IG (https://www.cardiff.ac.uk/centre-for-trials-research/research/studies-and-trials/view/enceph-ig)
Rwy'n agored i ddulliau cydweithredol ym meysydd heintiau ac imiwnedd.
Cyhoeddiad
2025
- Henley, J. et al. 2025. Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources. BMJ Open 15, article number: e093210. (10.1136/bmjopen-2024-093210)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15(1), article number: e084345. (10.1136/bmjopen-2024-084345)
2024
- Sandoe, J. A. T. et al. 2024. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy 79(11), pp. 2792-2800., article number: dkae246. (10.1093/jac/dkae246)
- Webb, E. J. D. et al. 2024. The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy 79(8), pp. 1831-1842., article number: dkae167. (10.1093/jac/dkae167)
- Webb, E. J. D. et al. 2024. Evidence of quality of life for hospitalised patients with COVID-19: a scoping review. Health Technology Assessment (10.3310/ATPR4281)
2023
- Henley, J. et al. 2023. Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: Qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study). BMJ Open 13(12), article number: e077117. (10.1136/bmjopen-2023-077117)
- Little, P. et al. 2023. Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT. Health Technology Assessment 27, article number: 9. (10.3310/DGBV3199)
2022
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH): protocol for a retrospective observational study. Methods and Protocols 5(6), article number: 95. (10.3390/mps5060095)
- Chatoo, S. A., Thomas-Jones, E., Pallmann, P. and Euden, J. 2022. Antibiotic prescribing in hospitalized patients with COVID-19 as a function of inflammatory markers in wave 1 versus wave 2: a systematic review. Presented at: BSAC Spring Conference 2022, 10 - 11 May 2022, Vol. 4. Vol. S.2., (10.1093/jacamr/dlac053.012)
- Euden, J. et al. 2022. PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open 12(6), article number: e063424. (10.1136/bmjopen-2022-063424)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalized patients during the first wave of COVID-19: the PEACH study. Presented at: Infection 2021: BSAC Winter Conference, Virtual, 9-10 December 2021, Vol. 4. Vol. 1., (10.1093/jacamr/dlac004.013)
2021
- Little, P. et al. 2021. Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care (ARTIC PC): a randomised placebo controlled trial. The Lancet 398, pp. 1417-1426. (10.1016/S0140-6736(21)01431-8)
- Powell, N. et al. 2021. Use of procalcitonin during the first wave of COVID-19 in the acute NHS hospitals: a retrospective observational study. Antibiotics 10(5), article number: 516. (10.3390/antibiotics10050516)
2013
- Euden, J., Mason, S. and Williams, A. J. 2013. Functional characterization of the cardiac Ryanodine receptor pore-forming region. PLoS ONE 8(6), article number: e66542. (10.1371/journal.pone.0066542)
- Euden, J., Mason, S., Viero, C., Thomas, N. L. and Williams, A. J. 2013. Investigations of the contribution of a putative glycine hinge to ryanodine receptor channel gating. Journal of Biological Chemistry 288(23), pp. 16671-16679. (10.1074/jbc.M113.465310)
2012
- Mason, S., Viero, C., Euden, J., Bannister, M., West, D., Chen, S. R. W. and Williams, A. J. 2012. The contribution of hydrophobic residues in the pore-forming region of the ryanodine receptor channel to block by large tetraalkylammonium cations and Shaker B inactivation peptides. The Journal of General Physiology 140(3), pp. 325-339. (10.1085/jgp.201210851)
- Viero, C., Thomas, N. L., Euden, J., Mason, S. A., George, C. H. and Williams, A. J. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Calcium Signaling. Advances in Experimental and Medical Biology Dordrecht: Springer, pp. 183-215., (10.1007/978-94-007-2888-2_8)
- Viero, C., Thomas, N. L., Euden, J., Mason, S., George, C. H. and Williams, A. J. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Islam, M. S. ed. Calcium Signaling. Advances in Experimental Medicine and Biology Vol. 740. Dordrecht: Springer, pp. 183-215., (10.1007/978-94-007-2888-2_8)
2010
- Carney, J., Mason, S. A., Viero, C. and Williams, A. J. 2010. The ryanodine receptor pore: Is there a consensus view?. In: Serysheva, I. I. ed. Structure and Function of Calcium Release Channels., Vol. 66. Current Topics in Membranes Elsevier Academic Press In, pp. 49-67., (10.1016/S1063-5823(10)66003-6)
2007
- Carney, J., East, J. M. and Lee, A. G. 2007. Penetration of lipid chains into the transmembrane surface of TbMscL. Biophysical Journal 92, pp. 3556-3563. (10.1529/biophysj.106.102210)
Articles
- Henley, J. et al. 2025. Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources. BMJ Open 15, article number: e093210. (10.1136/bmjopen-2024-093210)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15(1), article number: e084345. (10.1136/bmjopen-2024-084345)
- Sandoe, J. A. T. et al. 2024. A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19. Journal of Antimicrobial Chemotherapy 79(11), pp. 2792-2800., article number: dkae246. (10.1093/jac/dkae246)
- Webb, E. J. D. et al. 2024. The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy 79(8), pp. 1831-1842., article number: dkae167. (10.1093/jac/dkae167)
- Webb, E. J. D. et al. 2024. Evidence of quality of life for hospitalised patients with COVID-19: a scoping review. Health Technology Assessment (10.3310/ATPR4281)
- Henley, J. et al. 2023. Developing a model for decision-making around antibiotic prescribing for patients with COVID-19 pneumonia in acute NHS hospitals during the first wave of the COVID-19 pandemic: Qualitative results from the Procalcitonin Evaluation of Antibiotic use in COVID-19 Hospitalised patients (PEACH Study). BMJ Open 13(12), article number: e077117. (10.1136/bmjopen-2023-077117)
- Little, P. et al. 2023. Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT. Health Technology Assessment 27, article number: 9. (10.3310/DGBV3199)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients (PEACH): protocol for a retrospective observational study. Methods and Protocols 5(6), article number: 95. (10.3390/mps5060095)
- Euden, J. et al. 2022. PROcalcitonin and NEWS2 evaluation for Timely identification of sepsis and Optimal use of antibiotics in the emergency department (PRONTO): protocol for a multicentre, open-label, randomised controlled trial. BMJ Open 12(6), article number: e063424. (10.1136/bmjopen-2022-063424)
- Little, P. et al. 2021. Antibiotics for lower Respiratory Tract Infection in Children presenting in Primary Care (ARTIC PC): a randomised placebo controlled trial. The Lancet 398, pp. 1417-1426. (10.1016/S0140-6736(21)01431-8)
- Powell, N. et al. 2021. Use of procalcitonin during the first wave of COVID-19 in the acute NHS hospitals: a retrospective observational study. Antibiotics 10(5), article number: 516. (10.3390/antibiotics10050516)
- Euden, J., Mason, S. and Williams, A. J. 2013. Functional characterization of the cardiac Ryanodine receptor pore-forming region. PLoS ONE 8(6), article number: e66542. (10.1371/journal.pone.0066542)
- Euden, J., Mason, S., Viero, C., Thomas, N. L. and Williams, A. J. 2013. Investigations of the contribution of a putative glycine hinge to ryanodine receptor channel gating. Journal of Biological Chemistry 288(23), pp. 16671-16679. (10.1074/jbc.M113.465310)
- Mason, S., Viero, C., Euden, J., Bannister, M., West, D., Chen, S. R. W. and Williams, A. J. 2012. The contribution of hydrophobic residues in the pore-forming region of the ryanodine receptor channel to block by large tetraalkylammonium cations and Shaker B inactivation peptides. The Journal of General Physiology 140(3), pp. 325-339. (10.1085/jgp.201210851)
- Carney, J., East, J. M. and Lee, A. G. 2007. Penetration of lipid chains into the transmembrane surface of TbMscL. Biophysical Journal 92, pp. 3556-3563. (10.1529/biophysj.106.102210)
Book sections
- Viero, C., Thomas, N. L., Euden, J., Mason, S. A., George, C. H. and Williams, A. J. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Calcium Signaling. Advances in Experimental and Medical Biology Dordrecht: Springer, pp. 183-215., (10.1007/978-94-007-2888-2_8)
- Viero, C., Thomas, N. L., Euden, J., Mason, S., George, C. H. and Williams, A. J. 2012. Techniques and methodologies to study the ryanodine receptor at the molecular, subcellular and cellular level. In: Islam, M. S. ed. Calcium Signaling. Advances in Experimental Medicine and Biology Vol. 740. Dordrecht: Springer, pp. 183-215., (10.1007/978-94-007-2888-2_8)
- Carney, J., Mason, S. A., Viero, C. and Williams, A. J. 2010. The ryanodine receptor pore: Is there a consensus view?. In: Serysheva, I. I. ed. Structure and Function of Calcium Release Channels., Vol. 66. Current Topics in Membranes Elsevier Academic Press In, pp. 49-67., (10.1016/S1063-5823(10)66003-6)
Conferences
- Chatoo, S. A., Thomas-Jones, E., Pallmann, P. and Euden, J. 2022. Antibiotic prescribing in hospitalized patients with COVID-19 as a function of inflammatory markers in wave 1 versus wave 2: a systematic review. Presented at: BSAC Spring Conference 2022, 10 - 11 May 2022, Vol. 4. Vol. S.2., (10.1093/jacamr/dlac053.012)
- Euden, J. et al. 2022. Procalcitonin evaluation of antibiotic use in COVID-19 hospitalized patients during the first wave of COVID-19: the PEACH study. Presented at: Infection 2021: BSAC Winter Conference, Virtual, 9-10 December 2021, Vol. 4. Vol. 1., (10.1093/jacamr/dlac004.013)
Ymchwil
Diddordebau Ymchwil
- Heintiau, Llid ac Imiwnedd
- Sepsis
- Biofarcwyr a POCTs
- Stiwardiaeth Gwrthficrobaidd
- Meddygaeth Frys
- Dyfeisiau Meddygol
Grantiau:
2025: Cynllun Cyllid Integredig HCRW - Profion firaol anadlol wrth reoli INfants Febrile yn cyflwyno i ofal brys (REFINE): Astudiaeth beilot. (Cyd-arweinydd, arweinydd Astudiaeth CTR) £337,027)
2025: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Hap-dreial o therapi mewnwythiennol aminophylline, magnesiwm sylffad neu salbutamol ar gyfer asthma difrifol acíwt mewn plant a phobl ifanc (EVITA) (Cyd-Ymchwilydd, Arweinydd Astudiaeth CTR) £2,359,028.40
2025: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - EXamining antibiotics for ulCerated skIn cancer Excision Surgical Excision (EXCISE) (Cyd-Ymchwilydd) £1,486,597.90
2024: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Gwerthuso clinigol a chost-effeithiol TEstosteronE i wella ansawdd bywyd sy'n gysylltiedig â'r menopos (ESTEEM) (Cyd-Ymchwilydd, Arweinydd Astudiaeth CTR) £2,657,590.34
2023: Rhaglen Asesu Technoleg Iechyd (HTA) NIHR - Gwerthusiad ar hap o ganlyniadau clinigol gan ddefnyddio technolegau newydd i wneud y gorau o therapi gwrthficrobaidd (PROTECT), (Cyd-Ymchwilydd) £204,987
2023: Rhaglen Ymchwil NIHR er Budd Cleifion (RfPB) - Gwella cyfathrebu â pherthnasau mewn profedigaeth am dreialon brys a gofal critigol (ENHANCE) (Cyd-Brif Ymchwilydd, Arweinydd Astudiaeth CTR) £254,000
Bywgraffiad
Career Overview
2017 - date: Research Associate (Trial Manager), Division of Population Medicine, School of Medicine, Cardiff University
2007-2016: Research Associate, Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff Univeristy
2001-2003: Graduate Research Scientist, Health Protection Agency, Porton Down, Salisbury.
Education and Qualifications
2007: PhD (Biochemistry) School of Biological Sciences, University of Southampton.
'Effects of lipids on the structure of the Mechanosensitive channel, MscL'
A quantitative, lab based project using protein biochemical, biophysical and molecular biological techniques.
2001: BSc(hons) Human Biosciences, School of Biological Sciences, Plymouth University.
Modules included human genetics, applied immunology, applied toxicology, biochemistry, bacteriology & virology and cell biology.
Aelodaethau proffesiynol
Cymdeithas Cemotherapi Gwrthficrobaidd Prydain
Cynghrair GW4
UKTMN
Pwyllgorau ac adolygu
NIHR Adolygydd Cyfoed
Contact Details
+44 29225 10771
Neuadd Meirionnydd, Ystafell 708F, 7fed llawr., Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS